CRISPR Therapeutics shares are trading higher after Mizuho initiated coverage on the stock with a Buy rating and $82 price target.
Portfolio Pulse from Benzinga Newsdesk
Mizuho has initiated coverage on CRISPR Therapeutics with a Buy rating and a price target of $82. This has led to an increase in the trading of CRISPR Therapeutics shares.
September 27, 2023 | 6:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics' stock is trading higher following Mizuho's initiation of coverage with a Buy rating and a price target of $82.
The initiation of coverage by Mizuho with a Buy rating and a price target of $82 indicates a positive outlook for CRISPR Therapeutics. This has led to increased trading of the company's shares, suggesting that investors are reacting positively to the news. This is likely to have a short-term positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100